Clinical Trial

A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a phase 3, open-label, randomized, multinational study to evaluate the anti-tumor efficacy of golidocitinib versus investigator's choice in adult patients with relapsed/refractory peripheral T-cell lymphoma (r/r PTCL). This study will treat patients with pathologically confirmed PTCL who have relapsed after or been refractory/intolerant to at least one prior systemic treatment regimen(s).
Trial Details
NCT Number NCT07234162
Lead Sponsor Dizal Pharmaceuticals
Conditions Peripheral T-cell Lymphoma
Enrollment 218 participants
Start Date 2024-05-13
Primary Completion 2027-11-30 (estimated)
Study Completion 2028-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-08